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Abstract As the most common malignant tumor for fe-
males, breast cancer (BC) is a highly heterogeneous disease
regarding biological behaviors. Precisely targeted imaging
on BC masses and biomarkers is critical to BC detection,
treatment, monitoring, and prognostic evaluation. As an
important imaging technique, quantum dots (QDs)-based
imaging has emerged as a promising tool in BC researches
owe to its outstanding optical properties. However, few
reviews have been specifically devoted to discussing ap-
plications of QDs-based imaging in BC researches. This
review summarized recent promising works in QDs-based
tissue and in vivo imaging for BC studies. Physicochemical
and optical properties of QDs and its potential applications
were briefly described first. Then QDs-based imaging
studies in BC were systematically reviewed, including
tissue imaging for studying biomarkers interactions, and
evaluating prognostic biomarkers, in vivo imaging for
mapping axillary lymphatic system, showing BC xenograft
tumor, and detecting BC metastases. At last, the future
perspectives with special emphasis on the potential clinical
applications have also been discussed. Potential applica-
tions of QDs-based imaging on clinical BC in the future are
mainly focused on tissue study, especially in BC molecular
pathology due to its optimal optical properties and quan-
titative information capabilities on multiple biomarkers.
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MRI Magnetic resonance imaging
NIR Near-infrared
ALS Axillary lymphatic system
HER2 Human epidermal growth factor receptor-2
ER Estrogen receptor
PR Progesterone receptor
ALN Axillary lymph nodes
SLN Sentinel lymph node
PEG Polyethylene glycol
Introduction
Breast cancer (BC) is the most common malignant tumor
for females worldwide [1]. With the advancement in
screening tools and comprehensive therapies for BC, con-
siderable improvements have been achieved over the past
few decades [1–3]. It has been widely accepted that BC is a
highly heterogeneous disease, with different biological
behaviors for the same stage of BC patients [4]. Therefore,
personalized medicine determined by multiplex informa-
tion on prognosis is the main direction for BC therapy in
the future. For individualized cancer therapy, cancer
imaging including macroscopic cancer imaging techniques
(computed tomography, magnetic resonance imaging,
MRI; positron emission tomography and ultrasonography)
and microscopic cancer imaging techniques (hematoxylin-
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eosin, immunohistochemistry, and immunofluorescence)
play critical roles in cancer detection, treatment, prognosis
evaluation, and disease course monitoring.
Preventive and predictive oncology will be the direction
of future clinical oncology, which is different from tradi-
tional therapeutic oncology [5, 6]. The essence is to obtain
adequate information on prognosis from tumor tissues, and
to predict future biological behaviors of tumor. Eventually,
specific personalized treatment strategies are formulated
based on the integrated prognostic information. In this re-
gard, traditional imaging techniques could not satisfy the
need for acquiring more specific and unique information on
BC biology. For example, it has been well recognized that
tumor invasion and metastasis are closely associated with
coevolution of cancer cells and tumor microenvironment,
which involve multiple biomarkers [7, 8]. However, how to
simultaneously obtain multi-dimensional information from
both cancer cells and tumor microenvironment is a for-
midable challenge for traditional imaging techniques.
Therefore, new imaging techniques to reveal multi-di-
mensional information clearly and precisely are urgently
needed in cancer research.
Recently, nanotechnology has emerged as a promising
tool in biomedicine research. An important branch of
nanotechnology is optical-based nanoparticles imaging,
such as quantum dots (QDs)-based imaging, which has
showed promising potential applications in cancer research
[9, 10]. The majority of QDs are semiconductor
nanocrystals with many better optical properties than tra-
ditional organic dyes, such as high fluorescence intensity,
strong resistance to photobleaching and chemical degra-
dation, size-tunable emission wavelength and, large two-
photon cross section, simultaneous multiple fluorescence
under a single excitation source [9, 11–13]. Because of
these optical advantages, QDs-based imaging has been
widely applied in cancer researches. This review summa-
rizes the current status and future perspectives of QDs-
based tissue and in vivo imaging in BC researches, with
special emphasis on the potential clinical applications.
Physicochemical and optical properties of QDs
The majority of QDs are semiconductor nanocrystals with
core size ranging from 2 to 10 nm, composed of two types
of atoms from the II–VI group elements of periodic table of
chemical element [11, 12, 14, 15]. When QDs are excited
by an external high-energy light, the internal electron of
QDs will transform from its ground state to a higher level.
The high-level electron relaxes and returns to the ground
state, a photon is emitted producing fluorescence [11, 12,
16, 17]. The minimal energy required to excite an electron
from its ground state to a higher level is called as band gap
energy, which is dependent on the size of the complex, the
larger size, the smaller the band gap. Therefore, QDs have
an advantage of continuous and size-tunable emission
wavelength ranging from whole visible light to mid-in-
frared light regions (400–5000 nm) [16, 18, 19]. QDs also
has narrow emission and wide excitation spectrum advan-
tages, a property favoring multiplexed imaging under one-
excitation spectrum without mutual interference among
targeted signals [11, 12]. Because of the small size, the
entire QDs particle could behave like a single molecule
with the component atoms exciting and emitting light si-
multaneously to produce high signal intensity in the form
of strong fluorescence [12, 16, 17, 20].
For tumor applications, QDs are encapsulated with di-
verse types of amphiphilic polymers to make it more bio-
compatible and water-soluble [16, 17]. Those amphiphilic
polymers often carry chemically active groups, such as
carboxyl, hydroxyl, and thiol groups, which can couple
with modified functional agents, such as streptavidin, drug,
small molecule, DNA, and antibody. The modified QDs
could be used for tumor studies, such as biomarker detec-
tion [21, 22], tumor imaging [23, 24], tumor heterogeneity
demonstration [25–27], cancer diagnosis [16], treatment
[28], and monitoring [16, 29] (Fig. 1A).
Applications of QDs-based imaging in BC
One specific application of QDs is that it has a narrow
emission spectrum but a size-dependent tunable emission
wavelength ranging from visible to near-infrared (NIR)
light, and this unique property makes QDs-based imaging
widely applicable for tissue and in vivo BC studies. For
tissue studies, QDs-based imaging has been used to study
biomarkers interactions (Fig. 1B) and evaluate prognostic
biomarkers (Fig. 1C). For in vivo studies, QDs-based
imaging has been applied to map axillary lymphatic system
(ALS) (Fig. 1D), show BC xenograft tumor (Fig. 1E), and
detect BC metastases (Fig. 1F).
QDs-based imaging to study biomarkers
interactions
It has been well recognized that malignant biological be-
haviors of cancer are due to the interactions of key mole-
cules from both tumor cells and microenvironment [7, 8].
Therefore, it is important to develop a method to simulta-
neously demonstrate the interactions of different mole-
cules, so as to decipher the tumor biological behaviors
from a multivariate perspective instead of a univariate
perspective. Currently, many traditional methods are
available to obtain a single biomarker information at one
time, such as immunohistochemistry, immunofluorescence,
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and Western blotting. These methods, however, share one
common drawback, that is they cannot obtain in situ
quantitative information with morphological features for
multiple biomarkers.
One encouraging progress in this field is the develop-
ment of QDs-based multiplexed imaging that shows enor-
mous potentials for in situ multiplexed imaging to
simultaneously reveal the interactions of different mole-
cules [9, 30]. The technical procedures of QDs-based im-
muno-conjugation plus biotin-streptavidin imaging on
single biomarker and double biomarkers are illustrated in
Fig. 2A1 and A2. In our study, QDs-based quantitative and
in situ multiplexed imaging on human epidermal growth
factor receptor-2 (HER2) and estrogen receptor (ER) of BC
tissues was developed, which may help understand the
evolutionary process of BC heterogeneity [30]. For exam-
ple, it has been well known that HER2 level in BC is
closely related to BC progression, but direct visual evi-
dence from tissue level is lacking to support the conclu-
sion. QDs-based multiplexed imaging on HER2 and IV
collagen was applied in our study, and demonstrated the
invasive behaviors of BC by progressive degradation and
destruction IV collagen with the increase of HER2 ex-
pression level in BC tissue, especially at the invasion edge
(Fig. 2B1–B4) [31]. Based on QDs imaging on IV colla-
gen, patterns of tumor invasion were described as washing
pattern, ameba-like pattern, polarity pattern, and linear
pattern (Fig. 2C1–C4) [32]. These patterns clearly show
interactions between cancer cells and microenvironment
during different invasive periods. In addition, it has been
widely recognized that tumor microenvironment is a
powerful stimulation factor for cancer invasion and
metastasis. Interestingly, further study showed dynamic
changes in IV collagen during cancer invasion, which
implied the pulse-mode of cancer invasion and metastasis
(Fig. 2D1, D2) [33]. Yet, few studies could directly ob-
serve the co-expression and dynamics of multiple
biomarkers in tumor microenvironment. In addition, QDs-
based multiplexed imaging has also been employed to si-
multaneously reveal the dynamic interactions between
biomarkers in tumor microenvironment (IV collagen, tu-
mor angiogenesis and infiltrative macrophages) and cancer
cells (matrix metalloproteinase 9), by incorporating the
temporal and spatial dimensions [34].
QDs-based imaging to evaluate prognostic
biomarkers
Cancer outcome is the most important concern for on-
cologists and patients. TNM staging system is the universal
language to determine the clinical stages of cancer, predict
the prognosis, and guide the treatment options. For this
staging system, T describes primary tumor size and whe-
ther it has invaded nearby tissue, N describes nearby/re-
gional lymph nodes that are involved, and M describes
distant metastasis [35]. Currently, lymph node-negative BC
patients have been the majority of the new cases [36]. And,
with the advancement of mass screening programs and
improved detection facilities, the proportion of early BC
has been on steady increase over the past two decades. For
Fig. 1 Optical properties and potential applications of QDs in BC
researches. Commonly used QDs are core–shell structure encapsu-
lated with amphiphilic polymers carrying chemically active groups.
Compared with traditional organic dyes, QDs show excellent optical
properties (A). After being coupled with active molecules, QDs can
be adapted for tissues imaging, such as studying biomarker interac-
tions (B) and evaluating prognostic biomarkers (C), and for in vivo
imaging such as mapping ALS (D), showing BC xenograft (E) and
detecting BC metastasis (F) in BC researches
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those, early BC with both N and M information negative,
TNM staging system is no longer efficient as an informa-
tive tool to predict prognosis and guide treatment option
[5]. Therefore, much information closely related with BC
prognosis should be obtained from the BC tumor mass
itself [5, 36].
With the development of molecular biology, many
prognostic biomarkers hidden in BC mass have been dis-
covered. Specific labeling and accurate quantification of
those prognostic biomarkers are the key procedure to
evaluating BC prognosis. In our previous studies, QDs-
based imaging and quantitative spectral analysis on
biomarkers of BC were developed and showed good cor-
relation and consistency with conventional IHC, with better
image quality and sensitivity [25, 37, 38]. By this method,
a new indicator, total HER2 load was obtained integrating
information on BC tumor size and QDs-based HER2
quantification, which could better reveal BC heterogeneity
Fig. 2 QDs-based imaging for studying BC biomarker interactions.
Schematic plots of QDs-based single (A1) and double biomarkers
imaging (A2). Decrease of IV collagen (yellow arrows) with the
increase of HER2 (red arrows): HER2 (0), intact IV collagen (B1);
HER2 (?), IV collagen becomes unsmooth and thinner (B2); HER2
(2 ?), IV collagen becomes degraded (B3); HER2 (3?), complete IV
collagen degradation (B4). BC invasion patterns: Washing Pattern
(C1), Ameba-like Pattern (C2), Polarity Pattern (C3), and Linear
Pattern (C4). Dynamic changes of IV collagen implied the pulse-
mode of cancer invasion and metastasis: expansive growth of tumor
nests burst to form disseminations (D1), the process from growth to
burst is more quickly than the last (D2). ECM: extracellular matrix.
Reproduced with permission from Ref [31–33]
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and new subtypes than current methods [26]. Furthermore,
a new molecular classification system, 5 molecular sub-
types based on separate spectral quantification of HER2,
ER, and progesterone receptor (PR) was established
(Fig. 3) [27]. Significantly, this classification system by
simple QDs-based imaging was as informative as multi-
genes analysis with lower cost. Consequently, this method
could have more potentials in clinical applications than
multi-gene assays, especially in developing countries
where multi-genes analysis is expensive for patients [27].
Fig. 3 QDs-based imaging for evaluating BC prognostic biomarkers.
QDs-based imaging on HER2 (A1), ER (A2), and PR (A3) was
acquired, unmixed, and quantified by CRi Nuance software. Unmixed
images of HER2 (B1), ER (B2), and PR (B3). Survival analysis on
HER2 load (C1), hormone receptors (C2), and 5 molecular subtypes
(C3). HTH2: high total HER2 load; LTH2: low total HER2 load;
HHR: high hormone receptors; LHR: low hormone receptors; NHR:
negative hormone receptor. Reproduced with permission from Ref
[26, 27]
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These studies demonstrated that QDs-based multiplexed
imaging may be a promising strategy for quantitative and
more accurate diagnostic pathology.
QDs-based imaging to map ALS
ALS is the most important lymphatic drainage system and
main lymphatic metastasis routes of BC. Axillary lymph
nodes (ALN) dissection is performed to eliminate potential
lymphatic metastasis and to evaluate prognosis of BC.
Presently, lymph node-negative BC has been on the steady
increase worldwide, and minimal invasive surgery has been
advocated widely in clinical practices [36]. Under these cir-
cumstances, ALN dissection is not a preferred operation be-
cause it is not necessary in most BC patients and its
complications (postoperative upper limb edema and other
dysfunctions) is common in BC patients. Instead, increasing
attention has been focused on sentinel lymph node (SLN)
which is the first and inevitable site when lymph node
metastasis occurs in BC [39]. Detection of SLN is enough to
evaluate ALN status, as against systematic clearance.
Therefore, preoperative and intraoperative detection and
imaging of ALS is the key procedure in predicting lymph
metastasis, designing surgical plan, and evaluating prognosis.
Optical imaging is an important method to detect and
image lymph system. Compared with visible light, NIR
fluorescence has advantages in imaging lymph system due
to its high tissue penetration through the skin and subcu-
taneous tissues. NIR QDs with an emission wavelength
ranging from 700 to 2500 nm are suitable to map lym-
phatic system because tissue penetration depth of NIR
QDs[ 5 mm, which can penetrate the skin and subcuta-
neous tissues to realize lymph imaging in large animal
(such as pig). Simultaneously, QDs has a larger two-photon
cross section than conventional fluorescent dyes which can
avoid the interference of tissue autofluorescence and can
help achieve deep tissue imaging [13, 20]. Using such NIR
QDs, Kim et al. [24] first achieved mapping axillary SLN
of mouse and femoral SLN of pig. Many similar studies
attempted to map lymphatic system have been conducted
thereafter (Table 1).
A potential advantage of QDs-based imaging is that it
can simultaneously assess and distinguish lymphatic drai-
nages from multiple separate drainage areas, which is
difficult for traditional lymphangiography techniques, such
as X-ray, MRI, or radionuclide [47–49]. Hama et al. [47]
adopted two NIR QDs with different wavelengths to si-
multaneously map two lymphatic flow pathways from the
breast and the upper extremity. This method could visu-
alize lymphatic drainage territories of the two different
areas as well as lymphatic vessel in real time. Subse-
quently, as many as 5 separate drainage areas of lymph
nodes were successfully imaged by 5 kinds of QDs with
different emission spectra in mice models [43, 46]. In a
study by Kobayashi et al. [49], QDs-labeled melanoma
cells and optically labeled dendrimers were used to si-
multaneously visualize migration of melanoma cells and
the lymphatics in vivo. This method can provide a nonin-
vasive in vivo imaging to demonstrate the relationship
between cell migration and lymphatic drainage patterns.
Additionally, a strong fluorescence signal in SLN was de-
tected within several minutes after QDs injection and
maintained for over 24 h [44]. Durable and strong SLN
fluorescence makes it easier for detection and subsequent
managements (i.e., biopsy and dissection) of SLN.
Although there have been concerns that in vivo application
of QDs may cause nonspecific targeting to other tissues or
organs because the reticuloendothelial system could take
QDs [50], nonspecific targeting is not found in QDs-based
ALS imaging of BC [44].
QDs-based imaging to show BC xenografts
The optical advantages of QDs have also been applied to
target and image tumor xenografts (Table 2). In vivo
prostate cancer targeting and imaging by QDs was reported
by Gao et al. as early as 2004 [23]. We have also described
targeting and imaging of QDs coupled with alpha-feto-
protein monoclonal antibody in human hepatocellular
carcinoma xenografts of nude mouse as well as its lung
metastasis [51]. Similarly, QDs also could be conjugated
with biomarker of BC to develop an ideal probe for in vivo
targeting and imaging in BC. A study of Rizvi et al. [52]
demonstrated the successful applications of NIR QDs-
conjugated HER2 in fixed and live HER2-overexpressed
BC cells. In animal models, QDs-conjugated anti-HER2
antibody was applied to image HER2-overexpressed BC
xenografts and observed the delivery process of QDs from
blood circulation to cancer cell perinuclear region [53].
Animal model studies also found that the fluorescence of
QDs directly conjugated with anti-HER2 antibody was
stronger than that of traditional polyethylene glycol (PEG)-
coated QDs in visualizing HER2-positive BC xenograft
[54, 55]. In addition, complex of QDs and trastuzumab can
achieve high-resolution 3-dimensional target imaging in
BC-bearing mice [56]. Besides target imaging, the complex
containing QDs and trastuzumab may also have therapeutic
effect on BC. Targeted removal of tumor can help the
precise excision of tumor with minimal damage on normal
tissues. By the guidance of NIR QDs imaging on
xenografted tumor, targeted removal of subcutaneous tu-
mor was successfully performed [57]. Moreover, with the
development of fluorescence-mediated tomography, the
in vivo fluorescence imaging depth could reach as deep as
10 cm [58, 59], which may be useful to guide intraop-
erative surgery for deep BC mass in the near future.
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As an optimal probe, NIR QDs also can be linked with
other imaging materials to develop a multimodality probe,
which has multifunctional imaging capabilities in different
imaging conditions. A multimodality probe containing
magnetic iron oxides and QDs was developed by Tan et al.
to perform dual-modal image of MRI and QDs in BC-
bearing mice [60]. Subsequently, a multilayered, core/shell
nanoprobe containing ferric oxide (core), visible-fluores-
cent QDs (inner shell), and NIR QDs (outer shell) was
fabricated by Ma et al. [61] to conduct in vivo multi-
modality imaging. With mean size of 150 nm, competent
magnetic property, and dual fluorescence at 600 and
750 nm, this novel multilayered probe has been success-
fully conjugated with anti-HER2 antibody to achieve both
targeted MRI and NIR imaging of BC tumor in nude mice.
A dual-modality probe including QDs and magnetic Mn
was designed by Ding et al. [62] to achieve fluorescence
imaging and MRI of subcutaneous and intraperitoneal
Table 1 QDs-based imaging on ALS
Researches Study models Major findings
Helle et al. [40] Mouse Visualization of SLN on right axilla was achieved both in healthy and BC-bearing mice with indium-based
NIR QDs, a toxicity-reduced tracer
Pons et al. [41] Mouse Cadmium-free QDs with reduced toxicity were synthesized to visualize right axillary and lateral thoracic
lymph nodes of mouse
Pic et al. [42] Mouse Comparison between fluorescence imaging and mass spectroscopy for detection of QDs-based imaging of
axillary and lateral thoracic SLN was performed, confirming QDs imaging could be a better strategy
Kosaka et al.
[43]
Mouse Five QDs with different emission spectra were injected at five different sites of mice to simultaneously show
multi-color lymphatic imaging of neck lymph nodes, thoracic lymph nodes, and ALN
Robe et al. [44] Nude mouse ALN of nude mouse were identified by QDs and biological distribution of QDs in ALN was analyzed
Ballou et al.
[45]
Nude mouse Rapid migration of two PEG-coated NIR QDs from the tumor to surrounding lymph nodes (inguinal, axillary,
lumbar, and renal lymph nodes) was visualized in nude mice
Kobayashi et al.
[46]
Mouse Simultaneous imaging on deep cervical nodes, superficial cervical nodes, thoracic duct, lateral thoracic
nodes, and axillary nodes was achieved by 5 kinds of QDs with different emission spectra
Hama et al. [47] Mouse Simultaneously mapping two lymphatic flows from the breast and the upper extremity with two QDs under
an exciting light
Kim et al. [24] Nude mouse
& pig
Imaging on femoral SLN of pigs and axillary SLN of mouse was achieved for the first time by NIR QDs
Table 2 QDs-based imaging on BC xenografts
Researches Study model Major findings
Ma et al. [61] Nude mice
mouse
Anti-HER2 antibody was conjugated to the multilayered, core/shell nanoprobes containing magnetic ferric
oxide particles, visible-fluorescent QDs, and NIR QDs to simultaneously conduct MRI and fluorescence
imaging of BC-bearing nude mice
Balalaeva et al.
[54]
Nude mouse Fluorescent signal of QDs bound with anti-HER2 antibody was stronger than that of PEG-coated QDs in
visualizing HER2-positive BC xenograft
Tan et al. [60] Mouse A complex containing magnetic iron oxides and QDs was developed to perform multimodal image of MRI
and QDs in BC-bearing mice
Papagiannaros
et al. [65]
Mouse Anti-nucleosome antibody 2C5 was coupled to NIR QDs containing polymeric micelles to enhance signal
intensity of BC tumor and melanoma lung pseudometastasis in mice
Papagiannaros
et al. [55]
Mouse PEG-phospholipid micelle-encapsulated QDs developed in this study showed more rapid speed and higher
fluorescence in imaging and quantifying BC tumor of mice than PEG QDs
Park et al. [64] Nude mouse A dual-modality complex contained magnetic iron oxide nanoparticles, QDs, and anti-cancer drug was
synthesized to simultaneously perform NIR imaging, MRI, and therapy on BC tumor
Takeda et al. [56] Mouse Complex of QDs and trastuzumab was injected to BC-bearing mice to perform in vivo target image by a
high-resolution 3D microscopic system
Tada et al. [53] Mouse QDs-conjugated with anti-HER2 antibody was injected to mice-bearing HER2-overexpressed BC to
analyze its delivery process from blood circulation to cancer cell perinuclear region
Breast Cancer Res Treat (2015) 151:7–17 13
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tumors in nude mouse, respectively. This probe opens a
door for multimodality imaging and overcomes the short-
coming of QDs imaging in deep tissues. The heat produced
by QDs when excited by laser irradiation can be used for
highly sensitive imaging and selected destruction of deep
tumor. QDs embedded in quantum well was applied by
SalmanOgli et al. [63] to enhance sensitivity of thermal
detection on small tumor based on the difference of tem-
perature between tumor and normal tissue by computa-
tional model-based difference methods. Furthermore, a
complex containing QDs, iron oxide, and doxorubicin was
synthesized by Park et al. to perform QDs-based imaging,
MRI, and therapy on BC-bearing nude mice [64].
QDs-based imaging to detect BC metastasis
Targeted imaging and early detection of metastasis, the
major cause for cancer mortality, could help initiate ef-
fective therapy to improve patients’ prognosis. Current
imaging techniques are difficult to achieve early detection
as we required, because those imaging techniques can de-
tect a tumor only when the tumor cells grow up to change
the structure of normal tissue. But QDs-based imaging
could help achieve earlier detection by imaging on tumor
cells, even single tumor cell in vivo [29]. In a study by
Gupta et al. [66], BC cells were labeled with QDs to de-
velop BC brain metastasis model of nude mice, which was
used to demonstrate anti-metastatic effects of phenethyl
isothiocyanate. By QDs-based imaging, this study
demonstrated that phenethyl isothiocyanate not only sup-
press growth of brain metastasis, but also eradicate small
metastasizes in other sides.
Micrometastasis is an early metastasis which takes place
long before the development of obvious metastasis, and
such micrometastasis within the diameter of 0.2 to 2.0 mm
[35] is now considered as a powerful prognostic factor for
BC [67]. As a result, rapid, sensitive, and accurate detec-
tion of micrometastasis holds important clinical sig-
nificance in cancer therapy. At present, however, the
unsatisfactory fact is that the conventional techniques, such
as intraoperative frozen section examinations, often fail to
reveal such micrometastasis because of low resolution. To
tackle this problem, multi-color fluorescence imaging
could provide promising solution, but low photostability
and single-plexed imaging of traditional organic dyes limit
the application of these fluorescent agents in clinical set-
ting. In contrast, QDs could be developed to distinguish
rare target cells from non-target tissues due to their high
photostability and strong fluorescence intensity.
Another advantage of QDs-based imaging for mi-
crometastasis of BC is that it can rapidly distinguish small
metastasis from complex non-tumor tissues because of its
strong fluorescence and target imaging [29, 68].
Comparison between QDs-based double-staining and rapid
HE staining demonstrated that false-negative rate of QDs-
based double-staining was much lower than HE staining in
intraoperative diagnosis of BC lymph nodes micrometas-
tasis and isolated tumor cells [68]. In terms of monitoring
cancer cells metastasis process, QDs were also used to real-
time monitoring the detail metastasis process of BC cells in
nude mouse, which could observe the four initial steps of
cancer metastasis: cancer cells far from blood vessels in
tumor, near the vessel, in the bloodstream, and adherent to
the inner vascular surface in the normal tissues near tumor
[29]. Furthermore, a multimodality complex composed
with iron oxide and QDs particle was used to label BC cells
and track these cells in lymphatic system of mice with MRI
and optical imaging system [69]. Importantly, single cancer
cell within lymph nodes can also be clearly observed in real
time.
Limitations and future perspectives
QDs have demonstrated enormous potentials in BC re-
searches. However, some serious limitations including in-
herent toxicity, poor biocompatibility, and lack of
multiplexed imaging and analytical systems should be
systematically improved to further promote their use in
cancer studies. Of these limitations, toxicity and biocom-
patibility are the main concerns, especially for in vivo
study. Most of the currently used QDs contain heavy metal
elements such as Cd, Te, As, Pb, and Hg [9, 19, 20], posing
potential adverse effects on living systems. Although some
studies revealed no toxic effect on culture cells and ex-
perimental animals [41, 51, 52], the long-term effect on
living systems is unknown. A study by Chan et al. [70]
indicated that the heavy metal core QDs could induce
early-stage mouse blastocyst death both in vitro and in vi-
vo. Furthermore, QDs can directly penetrate placental
barrier to harm fetal development or even destroy fetuses,
and the penetration behavior could not be eliminated by
coating with PEG or SiO2 [71]. As an external material,
QDs always accumulate into reticuloendothelial system
(e.g., liver, spleen, and kidney) whose clearance rate from
the body is very low [51, 71]. Therefore, those QDs con-
taining heavy metals should not be considered for in vivo
application in clinical BC. Fortunately, some low-toxic or
even non-toxic QDs, such as C-QDs, graphene QDs, silicon
QDs, and silver QDs have been developed recently, which
may avoid the heavy metals and have superior optical
properties than traditional semiconductor heavy metal-
contained QDs [10, 72, 73].
In the future, QDs will be used in BC researches more
frequently and widely because of its excellent optical
properties. With the advancement of fluorescence-mediated
14 Breast Cancer Res Treat (2015) 151:7–17
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tomography, tumor located in deep tissue ([10 cm) will be
revealed more clearly [58, 59], which may fully satisfy the
need for imaging in BC. In terms of tissue study, QDs-
based imaging had showed its optimal applicability in
imaging acquisition and quantification of single and mul-
tiple biomarkers. So QDs-based imaging on tissues could
be the main direction for clinical applications. By QDs-
based imaging, co-expression, and coevolution of multiple
biomarkers in cancer cells and microenvironment can be
well studied. Simultaneously, prognostic values of those
biomarkers could also be more accurately evaluated, which
will effectively push forward the progress of molecular
pathology and promote the transition to preventive and
predictive oncology.
Conclusions
As an optimal imaging technique, QDs-based imaging has
opened up a new field in BC research. Potential applica-
tions of QDs-based imaging on BC in the future are mainly
focused on tissue study, especially in BC molecular
pathology due to its optimal optical properties and quan-
tified information abilities on multiple biomarkers.
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